தோல் நோய் மெய்நிகர் வசந்த மாநாடு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Dermavant Sciences: Dermavant Announces Tapinarof Data Presentation at the Innovations in Dermatology Conference
Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced that an abstract containing interim analysis data from Dermavant s PSOARING 3 long-term, open-label safety study for tapinarof for the treatment of psoriasis in adults will be presented in poster format during the upcoming Innovations in Dermatology Virtual Spring Conference 2021, held from March 16-20, 2021.
The following poster will be viewable on the conference platform for the entirety of the conference:
Title:
Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Interim Analysis of a Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent ....

United States , Bruce Strober , April Armstrong , Laurence Watts , Annam Tallman , Robert Bissonnette , Mark Lebwohl , Angela Salerno Robin , Philipm Brown , Kostenloser Wertpapierhandel , Kara Stancell , Andrew Blauvelt , Roivant Sciences , Program For Tapinarof , Dermavant Sciences , Linkedin Dermavant Sciences , Investor Relations Corporate Communications , Dermatology Virtual Spring Conference , Tapinarof Cream , Once Daily , Plaque Psoriasis , Interim Analysis , Long Term Extension Trial , Linda Stein Gold , Leon Kircik , North America ,